Furthermore, H5CmTERT-Ad/TRAIL elicited a more potent cancer cell-killing effect than H5CmTERT-Ad did during normoxia (P < 0.05 for U87MG, P < 0.05 for U251N, respectively) and hypoxia (P < 0.01 for U87MG, P < 0.05 for U251N, respectively). This evidence concerns the gene TNFSF10 and cancer.